Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Abstract

BIM 23014 (BIM) is a long-acting octapeptide somatostatin analog. We studied the effects of this analog on the secretion of GH, TSH, and gastroenteropancreatic hormones [secretin, motilin, and pancreatic polypeptide (PP)] in normal men. In the first protocol three BIM doses (125, 250, and 500 μg) and vehicle were administered sc in random order at 2000 h to eight normal young men. Plasma GH concentrations decreased during the first part of the night only after the highest dose (P < 0.05). Plasma secretin levels did not change, while plasma motilin decreased after the 250- and 500-μg doses (P = 0.05 and P = 0.02, respectively), and plasma PP decreased after all three doses (P < 0.05, P < 0.01, and P < 0.01, respectively) during the first part of the night. In the second protocol, eight men received BIM, administered by constant sc infusion during the night in a dose of 2 mg/12 h, or vehicle, either alone or in association with a 10 ng/kg·min iv GHRH or vehicle infusion. Nocturnal GH secretion was suppressed by the BIM infusion (P < 0.001). GH secretion, stimulated by GHRH infusion (P < 0.001), was reduced by concomitant BIM infusion (P < 0.001) and was pulsatile during the combined infusions. BIM infusion suppressed the physiological nighttime rise in plasma TSH levels. Plasma motilin and PP levels were reduced by BIM, when administered either alone or in combination with GHRH.

We conclude that: 1) BIM is capable of reducing GH secretion when administered sc in a dose of 500 μg and of abolishing nocturnal GH secretion when constantly infused at a dose of 2 mg/12 h; 2) BIM, constantly infused, reduces the nocturnal rise in TSH secretion; and 3) motilin and PP secretion are more sensitive than that of GH to BIM, as they are reduced by a lower dose

This content is only available as a PDF.
Copyright © 1989 by The Endocrine Society
Issue Section:
Articles
You do not currently have access to this article.
Download all slides